NCT01459718View on ClinicalTrials.gov

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Transfusion-dependent β-thalassemia PatientsCardiac Iron Overload
Interventions
DRUG

Deferasirox

20-40 mg/kg/day orally, once daily

DRUG

Deferoxamine (DFO)

40 mg/kg/day subcutaneous (sc) infusion, 3-4 days per week

Trial Locations (4)

11527

Novartis Investigative Site, Athens

GR-115 27

Novartis Investigative Site, Athens

GR

Novartis Investigative Site, Athens

265 00

Novartis Investigative Site, Pátrai

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY